Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Abstract

Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: Hazard ratio [HR], 1.09; 95%confidence interval [CI], 1.01-1.19; P=.0360; Schmitz: HR, 1.13; 95%CI, 1.02-1.26; P=.0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95%CI, 1.00-1.58; P=.0455), but not GCHOP (HR, 0.91; 95%CI, 0.69-1.20; P=.50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95%CI, 0.44-1.02; P= .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95%CI, 1.00-2.50; P= .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor FcγRIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95%CI, 1.04-4.50; P=.0378), but not G-CHOP (HR, 1.37; 95%CI, 0.66-2.87; P=.3997). This effect was independent of established prognostic biomarkers. High FcγRIIB/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP/G-CHOP.